Gold prices steady above $3,400/oz on rate cut bets; PCE data awaited
LONDON - Kromek Group plc (AIM:LON:KMK), a detection technology company, revealed plans to scale its business to achieve revenues exceeding £60 million with a 30% EBITDA margin as part of its growth strategy presented at its capital markets day on Wednesday.
The company, which specializes in advanced imaging and CBRN (Chemical, Biological, Radiological and Nuclear) detection markets, also announced it will begin reporting revenue by division starting with its upcoming financial results for the year ended April 30, 2025.
Historical division revenue figures disclosed at the event showed CBRN Detection generated £10.4 million in fiscal 2024, up from £8.6 million in 2023, while Advanced Imaging contributed £9.0 million, compared to £8.7 million the previous year.
In a May 8 trading update, Kromek stated it expects to report fiscal 2025 revenue of at least £26 million, representing year-on-year growth of at least 34%, attributed to its partnership with Siemens (ETR:SIEGn) Healthineers.
The capital markets day, held at Cavendish Capital Markets’ London offices, provided institutional investors and analysts an opportunity to meet the leadership team and hear from industry representatives. No additional material information beyond the previously announced growth targets and historical divisional breakdown was disclosed.
The company will make presentation materials and a recording available on its website following the event. Kromek also plans to host a separate online Q&A session for retail investors on June 25.
Based in County Durham, UK, Kromek develops radiation detection and bio-detection technology solutions with manufacturing operations in both the UK and US, according to the press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.